Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 10/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.32 |
| ▸ | PDE4A | P27815 | 2/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17363566 | 1.00 | P2RY12 (0.34) | P2RY12CYP1A2STING1PDE4APDE4B | |
| SCHEMBL17363731 | 0.89 | CYP1A2 (0.40) | CYP1A2STING1PDE4APDE4BPDE4C | |
| SCHEMBL17363728 | 0.89 | CYP1A2 (0.40) | CYP1A2STING1PDE4APDE4BPDE4C | |
| SCHEMBL1797958 | 0.83 | PDE4A (0.44) | CYP1A2STING1PDE4APDE4BPDE4C | |
| SCHEMBL1795561 | 0.78 | UBA6 (0.48) | — | |
| SCHEMBL18486383 | 0.77 | STING1 (0.35) | P2RY12CYP1A2STING1PDE4APDE4B | |
| SCHEMBL18486384 | 0.77 | STING1 (0.35) | P2RY12CYP1A2STING1PDE4APDE4B | |
| SCHEMBL8939099 | 0.76 | STING1 (0.38) | STING1ADORA3 | |
| SCHEMBL8939101 | 0.76 | STING1 (0.38) | STING1ADORA3 | |
| SCHEMBL5963251 | 0.76 | STING1 (0.38) | STING1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10378011-B2 | Oligonucleotide | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-08-13 | — | — | US | disclosed |
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-07-09 | — | — | US | disclosed |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-14 | — | — | US | disclosed |
| US-20150376611-A1 | OLIGONUCLEOTIDE | KYOWA KIRIN CO., LTD. (JP) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10378011-B2 | Oligonucleotide | HNRNPA3, AGO2, RBM3 | P2RY12 4787/4885CYP1A2 4285/4885STING1 1227/4885 |
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | RNGTT, UPF1, NSUN3 | P2RY12 3118/4885CYP1A2 1890/4885STING1 1024/4885 |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | RNGTT, UPF1, NSUN3 | P2RY12 3171/4885CYP1A2 1905/4885STING1 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.